This is a StreetInsider.com Premium Only Page

DURECT Corp (DRRX) – StreetInsider.com Reports

Nov 8, 2023 04:26 PM Jones Trading Downgrades Durect Corp (DRRX) to Hold

Nov 8, 2023 07:47 AM Durect Corp (DRRX) PT Lowered to $8.50 at Northland Capital Markets

Nov 8, 2023 06:26 AM H.C. Wainwright Downgrades Durect Corp (DRRX) to Neutral, 'AHFIRM disappoints'

Nov 7, 2023 04:02 PM DURECT Corp (DRRX) Reports Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Nov 7, 2023 04:01 PM DURECT Corp (DRRX) Halted, News Pending

Sep 14, 2023 08:21 AM Northland Capital Markets Starts Durect Corp (DRRX) at Outperform, 'AHFIRM Topline Data Anticipated in 4Q23'

Aug 11, 2023 06:57 AM Durect Corp (DRRX) PT Lowered to $27 at H.C. Wainwright

Aug 10, 2023 06:33 AM Durect Corp (DRRX) PT Lowered to $41 at Cantor Fitzgerald

Jul 20, 2023 08:01 AM DURECT Corp (DRRX) Prices 2.99M Share Offering at $5.015/sh

May 8, 2023 04:19 PM DURECT Corp (DRRX) Misses Q1 EPS by 48c

Apr 10, 2023 06:00 AM DURECT Corp (DRRX) Announces Peer-Reviewed Publication of Additional Data from Previously Completed Phase 2a Study of Larsucosterol

Mar 21, 2023 04:30 PM DURECT Corp (DRRX) Appoints Gail Maderis as Board Chair

Mar 13, 2023 04:22 PM Jones Trading Starts Durect Corp (DRRX) at Buy

Mar 8, 2023 06:07 AM Durect Corp (DRRX) PT Lowered to $32 at H.C. Wainwright

Feb 6, 2023 08:10 AM DURECT Corp (DRRX) Announces $10 Million Registered Direct Offering of Common Stock and Warrants (earlier)

Dec 7, 2022 06:02 AM Durect Corp (DRRX) PT Raised to $32 at Oppenheimer

Dec 6, 2022 06:38 AM Durect Corp (DRRX) PT Raised to $35 at H.C. Wainwright

Nov 29, 2022 06:21 AM DURECT Corp (DRRX) Announces 1-for-10 Reverse Stock Split

Sep 26, 2022 08:33 AM DURECT Corp (DRRX), Innocoll Announce U.S. launch of POSIMIR

Aug 4, 2022 04:45 PM DURECT Corp (DRRX) Reports In-Line Q2 EPS

Jul 5, 2022 08:30 AM DURECT Corp (DRRX) Appoints Timothy M. Papp as Chief Financial Officer

Mar 7, 2022 04:21 PM DURECT Corp (DRRX) Tops Q4 EPS by 2c

Dec 22, 2021 07:31 AM DURECT Corp (DRRX) and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR

Dec 9, 2021 01:37 PM DURECT Corp (DRRX) Director Benito Buys 20K Shares

Nov 3, 2021 07:30 AM Durect Corp (DRRX) PT Lowered to $6 at Oppenheimer

Nov 2, 2021 04:26 PM DURECT Corp (DRRX) Tops Q3 EPS by 1c

Jul 30, 2021 09:53 AM Durect Corp (DRRX) PT Lowered to $7 at Oppenheimer

Jul 29, 2021 04:58 PM DURECT Corp (DRRX) Reports In-Line Q2 EPS

Jun 23, 2021 09:06 AM DURECT Corp (DRRX) Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at EASL

Mar 9, 2021 09:06 AM DURECT Corp (DRRX) Reports Publication of DUR-928's Mechanism of Action

Mar 4, 2021 04:28 PM DURECT Corp (DRRX) Misses Q4 EPS by 1c, Revenues Miss

Feb 4, 2021 09:27 AM Pre-Open Stock Movers 02/04: (AVXL) (SKLZ) (EBAY) Higher; (LCI) (ISR) (DRRX) Lower (more...)

Feb 4, 2021 09:20 AM DURECT Corp (DRRX) Prices $42.5 Million Public Offering of Common Stock

Feb 3, 2021 06:10 PM After-Hours Stock Movers 02/03: (AVXL) (APPS) (ALGN) Higher; (LCI) (ISR) (DRRX) Lower (more...)

Feb 3, 2021 04:02 PM DURECT Corp (DRRX) to Offer Common Stock

Feb 2, 2021 03:22 PM Durect Corp (DRRX) PT Raised to $8 at Oppenheimerm Following Clinical Update

Feb 2, 2021 08:03 AM DURECT Corp (DRRX) Announces U.S. FDA Approval of POSIMIR For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

Jan 25, 2021 08:33 AM DURECT Corp (DRRX) Reports First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

Jan 5, 2021 08:34 AM DURECT Corp (DRRX) Announces Gail J. Maderis and Mohammad Azab to Board

Dec 16, 2020 08:36 AM DURECT Corp (DRRX) Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis

Dec 7, 2020 11:16 AM DURECT Corp (DRRX) to Sell its LACTEL Absorbable Polymer Product Line to Evonik for $15 Million

Nov 13, 2020 09:01 AM DURECT Corp (DRRX) Reports Additional Safety Data & Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients

Nov 2, 2020 04:24 PM DURECT Corp (DRRX) Misses Q3 EPS by 1c

Oct 30, 2020 05:20 AM Chardan Capital Markets Starts Durect Corp (DRRX) at Buy

Oct 12, 2020 05:02 AM RHB Research Starts Durect Corp (DRRX) at Buy (1)

Oct 5, 2020 08:34 AM DURECT Corp (DRRX) to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting

Sep 23, 2020 08:32 AM DURECT Corp (DRRX) Reports First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

Sep 22, 2020 08:33 AM DURECT Corp (DRRX) Announces Design of Phase 2b AH Study (AHFIRM)

Aug 27, 2020 08:36 AM DURECT Corp (DRRX) Highlights Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at EASL 2020 Meetings

Aug 4, 2020 07:51 AM Durect Corp (DRRX) DUR-928 Timelines Remain On-Track - Cantor Fitzgerald